Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA

By Alain R. Thierry, F. Moulière, S. Messaoudi, C. Mollevi, E. Lopez-Crapez, F. Rolet, B. Gillet, C. Gongora, P. Dechelotte, B. Robert and 10 more. Nature Medicine, 2014

647 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/a6f48579b1fb642568a52ba3765d43b8829d5509

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Jay Shendure

Citations in the corpus

• Origins, structures, and functions of circulating DNA in oncology (2016, background): “examining the KRAS/BRAF mutations in colorectal cancer patients [70].”
• Fragment Length of Circulating Tumor DNA (2016, methodology): “Emerging approaches to improve detection of ctDNA include amplicon-based strategies in colorectal cancer [14] and integrated digital error suppression during deep sequencing in lung cancer [15].”
• RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics (2015, neutral): “…evaluated as liquid biopsies, including plasma DNA (Bettegowda et al., 2014; Chan et al., 2013; Diehl et al., 2008; Murtaza et al., 2013; Newman et al., 2014; Thierry et al., 2014) and circulating tumor cells (Bidard et al., 2014; Dawson et al., 2013; Maheswaran et al., 2008; Rack et al., 2014).”